IBEX 35
11.154,60 +170,90 (+1,56%) Euro Stoxx 50
5.006,85 +67,84 (+1,37%) Dólar/Euro
1,0699 -0,0034 (-0,32%) Petróleo Brent
89,36 +0,35 (+0,39%) Oro
2.349,60 +7,10 (+0,30%) Bitcoin EUR
59.043,12 -1.242,22 (-2,06%)
Bruker Corporation (BRKR)
Después del cierre:
Bruker Corporation
40 Manning Road
Billerica, MA 01821
United States
978 663 3660
https://www.bruker.com
Sector(es): Healthcare
Sector: Medical Devices
Empleados a tiempo completo: 9707
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Gerald N. Herman | Executive VP & CFO | 1,13M | N/A | 1958 |
| Dr. Mark R. Munch Ph.D. | Corporate Executive VP and President of Bruker Nano Group & Corporate | 1,63M | N/A | 1962 |
| Mr. Juergen Srega | President of Bruker CALID Group & Bruker Daltonics Division | 842,19k | N/A | 1955 |
| Dr. Falko Busse Ph.D. | President of Bruker BioSpin Group | 945,18k | N/A | 1967 |
| Dr. Frank H. Laukien Ph.D. | Chairman, CEO & President | 1,82M | 3,25M | 1960 |
| Mr. Justin Joseph Ward | Senior Director of Investor Relations & Corporate Development | N/A | N/A | N/A |
| Mr. J. Brent Alldredge J.D. | General Counsel & Secretary | N/A | N/A | 1975 |
| Stacey Desrochers | Treasurer & Director of Investor Relations | N/A | N/A | N/A |
| Dr. Burkhard Prause Ph.D. | President and CEO of Bruker Energy & Supercon Technologies, Inc. | 595,96k | N/A | 1967 |
Descripción
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Gobierno corporativo
El ISS Governance QualityScore de Bruker Corporation, a día 1 de abril de 2024, es 5. Las puntuaciones base son Auditoría: 7; Tablero: 7; Derechos de los accionistas: 4; Compensación: 3.
